当前位置: X-MOL 学术J. Immunol. Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Prealbumin-to-Globulin Ratio Can Predict the Chemotherapy Outcomes and Prognosis of Patients with Gastric Cancer Receiving First-Line Chemotherapy.
Journal of Immunology Research ( IF 4.1 ) Pub Date : 2020-08-05 , DOI: 10.1155/2020/6813176
Zhuo Wang 1 , Liqun Zhang 1, 2 , Jingyan Wang 3 , Yuanhe Wang 1 , Qian Dong 1 , Haiyan Piao 1 , Qiwei Wang 1 , Jingdong Zhang 1
Affiliation  

Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer-related mortality worldwide. Inflammation and the nutritional status of patients with GC are important factors affecting the therapeutic effect and prognosis. Inflammatory and nutrition-related markers have been shown to be prognostic factors for patients with GC. However, few studies have investigated the relationship of the prealbumin-to-globulin ratio (PGR) with the prognosis of GC patients. The objective of the present study was to examine whether pretreatment PGR is related to the prognosis and chemotherapy outcomes of in-patients with advanced GC undergoing first-line chemotherapy. We retrospectively reviewed the data of 281 patients with unresectable GC from January 2013 to January 2018. The receiver operating characteristic curve analysis determined the cut-off values for the PGR. The relationship between the PGR and chemotherapy effectiveness was evaluated using the chi-square test. Kaplan-Meier’s method was used to plot progression-free survival (PFS) and overall survival (OS) curves, using multivariable Cox regression analysis to identify promising predictors of mortality. The cut-off value for the PGR was 7.21. The high-PGR (≥7.21) group had a higher disease control rate than that of the low-PGR group (93.66% vs. 78.42%, ). Kaplan-Meier’s analysis showed significantly higher median PFS (189 vs. 125 days, ) and OS (350 vs. 288 days, ) in the high-PGR group. The multivariate analyses revealed that a high PGR is an independent protective factor in patients with advanced GC, both in terms of PFS (hazard ratio [HR]: 0.672; 95% confidence interval [CI]: 0.527–0.857; ) and OS (HR: 0.675; 95% CI: 0.530–0.861; ). In conclusion, the prechemotherapy PGR can accurately predict the chemotherapy outcome, PFS, and OS of patients with advanced GC. Therefore, medical practitioners can utilize the PGR as a novel dependable prognostic tool to weigh the prognosis of patients with GC.

中文翻译:

前白蛋白与球蛋白的比例可以预测接受一线化疗的胃癌患者的化疗结果和预后。

胃癌(GC)是全球第五大最常见的癌症,也是与癌症相关的死亡率的第三大主要原因。GC患者的炎症和营养状况是影响疗效和预后的重要因素。炎症和营养相关的标志物已被证明是GC患者的预后因素。然而,很少有研究调查前白蛋白与球蛋白之比(PGR)与GC患者预后的关系。本研究的目的是检查治疗前PGR是否与一线化疗的晚期GC住院患者的预后和化疗结果有关。我们回顾性研究了2013年1月至2018年1月的281例不可切除的GC患者的数据。接收机工作特性曲线分析确定了PGR的临界值。使用卡方检验评估了PGR与化疗效果之间的关系。Kaplan-Meier方法用于绘制无进展生存期(PFS)和总体生存期(OS)曲线,并使用多变量Cox回归分析来确定有希望的死亡率预测指标。PGR的临界值为7.21。高PGR(≥7.21)组的疾病控制率高于低PGR(93.66%对78.42%,使用多变量Cox回归分析来确定有希望的死亡率预测因子。PGR的临界值为7.21。高PGR(≥7.21)组的疾病控制率高于低PGR(93.66%对78.42%,使用多变量Cox回归分析来确定有希望的死亡率预测因子。PGR的临界值为7.21。高PGR(≥7.21)组的疾病控制率高于低PGR(93.66%对78.42%,)。Kaplan-Meier的分析显示,PFS中位数显着较高(189天比125天,和操作系统(350天和288天,在高PGR组中。多元分析表明,就PFS而言,高PGR是晚期GC患者的独立保护因素(危险比[HR]:0.672; 95%置信区间[CI]:0.527-0.857; CFS:0.527-0.857。和OS(HR:0.675; 95%CI:0.530-0.861;)。总之,化疗前的PGR可以准确预测晚期GC患者的化疗结果,PFS和OS。因此,从业人员可以利用PGR作为一种可靠的新型预后工具来权衡GC患者的预后。
更新日期:2020-08-06
down
wechat
bug